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The role of peroxisome proliferator-activated receptors (PPARs) in altering lipid and glucose metabolism is well established.
More recent studies indicate that PPARs also play critical roles in controlling immune responses. We and others have previously
demonstrated that PPAR-γ agonists modulate the development of experimental autoimmune encephalomyelitis (EAE), an animal
model of multiple sclerosis (MS). This review will discuss the cellular and molecular mechanisms by which these agonists are
believed to modulate disease. The therapeutic potential of PPAR-γ agonists in the treatment of multiple sclerosis will also be
considered.
Copyright © 2008 Paul D. Drew et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1. INTRODUCTION
Multiple sclerosis (MS) is the second most common neu-
rologic disorder of young adults, behind neurotrauma.
Approximately 350000–400000 individuals have physician
diagnosed MS in the United States alone. MS is commonly
diagnosed around the third decade of life and many patients
suﬀer the devastating eﬀects of the disease for much of their
adult lives. The etiology of MS is not completely understood
but is believed to result from a combination of genetic
and environmental factors. The disease is characterized by
inﬂammation of the central nervous system (CNS), de-
myelination, and either relapsing-remitting or progressive
clinical presentations. Similarities to experimental autoim-
mune encephalomyelitis (EAE), an established animal model
of MS which is elicited following generation and attack
of autoreactive T cells against brain tissues suggests an
autoimmune origin for MS. In addition to autoreactive T
cells, other peripheral immune cells including B cells, mon-
ocytes, and dendritic cellsmay play a rolein thepathogenesis
associatedwithMS.Inaddition,residentCNScellsincluding
chronically activated glial cells are believed to play a role in
disease pathogenesis [1].
Nuclear receptors are a family of transcription factors
that regulate gene expression in response to ligand binding.
Nuclear receptor superfamily members include peroxisome
proliferator-activated receptors (PPARs) as well as andro-
gen, estrogens, progesterone, thyroid, and glucocorticoid
receptors. Additional orphan nuclear receptors exist for
which ligands have not been identiﬁed. The critical role of
PPARs in modulating glucose and lipid metabolism has been
extensively documented [2]. More recently, a role for PPARs
inalteringimmuneresponseshasbeenestablished.Arolefor
PPARs in modulation of immune responses was suggested
by the observation that indomethacin, a nonsteroidal anti-
inﬂammatory drug (NSAID) binds PPAR-γ. Furthermore,
it was documented that PPAR-γ is expressed by cells of
the monocyte/macrophage lineage. These observations led
to seminal studies demonstrating that PPAR-γ agonists sup-
press the activation of monocyte/macrophages [3, 4]. Three
PPAR isoforms, PPAR-α,- β/δ,a n d- γ, have been identiﬁed.
These receptors exhibit distinct tissue expression patterns
and ligand speciﬁcities [2, 5]. Eicosanoids, polyunsaturated
fatty acids, and the cyclopentenone prostaglandin 15d-PGJ2
are naturally occurring PPAR-γ ligands. Synthetic PPAR-γ
ligands include thiazolidinediones which are used for the
treatment of type II diabetes.
As transcription factors, PPARs primarily function
to regulate the expression of speciﬁc genes. Similar to
other nuclear receptors, PPARs bind DNA and regulate
gene expression as dimers. PPARs form heterodimers with2 PPAR Research
retinoid-X-receptors (RXRs), and bind DNA at conserved
peroxisome-proliferator response elements (PPREs) present
in the promoter of PPAR-responsive target genes. Upon
ligand binding, the PPAR/RXR heterodimer associates
with coactivator complexes, binds PPREs, and activates
the transcription of PPAR-responsive genes. In contrast,
PPAR/RXR heterodimers not bound by ligand associate
with corepressor complexes resulting in suppression of
gene transcription [2]. PPAR ligands principally activate
transcription of genes encoding proteins important in lipid
and glucose metabolism by triggering PPAR/RXR binding
to PPREs present in the promoters of these genes. In
contrast, PPAR agonists generally suppress the expression
of genes encoding proinﬂammatory molecules through a
mechanism not involving PPAR/RXR binding to PPREs.
This mechanism, termed receptor-dependent transrepres-
sion, is believed to occur through physical interaction
between PPAR/RXR and other transcription factors which
normally activate transcription of proinﬂammatory genes.
Physical interaction with PPAR/RXR inhibits binding of
these transcription factors to response elements present
on genes encoding proinﬂammatory molecules, thus sup-
pressing the activation of these genes. Receptor-dependent
transrepression may also result from PPAR/RXR interaction
with transcriptional coactivator or corepressor molecules
that are in limited supply, or PPAR/RXR interactions with
the basal transcription machinery [6, 7]. PPAR-γ agonists
inhibit transcription factors including NF-κB, AP-1, and
STAT-1 from activating gene expression through receptor-
dependent transrepression [8]. The mechanisms resulting
in receptor-dependent transrepression have remained a
mystery. However, recent pioneering work by Glass et al. has
begun to elucidate the molecular mechanisms that control
receptor-dependent transrepression of NF-κBr e s p o n s i v e
genes. These studies demonstrate that in the presence of
PPAR-γ ligands, PPAR-γ can conjugate with small ubiquitin-
like modiﬁer-1 (SUMO1) resulting in the sumoylation of
PPAR-γ.S um o yl at edPP A R -γ binds the corepressor molecule
NCoR which maintains the promoters of responsive genes in
a repressed state, even in the presence of NF-κB activating
stimuli. The mechanisms by which NF-κB responsive genes
are believed to remain in a repressed state following sumoy-
lation of PPAR-γ and consequent association with NCoR are
believed to involve inhibition of the recruitment of ubiquitin
conjugating enzymes to the corepressor complex following
physical association of sumoylated PPAR-γ with NCoR [9–
11]. Interestingly, recent studies have demonstrated that in
addition to PPAR-γ, liver X receptor (LXR) mediated tran-
srepression involves sumoylation of receptor and association
of NCoR [12]. This suggests the possibility of a general
mechanism of transrepression by PPARs and LXRs.
As stated above, PPAR-γ agonists can regulate gene
expression in a receptor-dependent manner through recep-
tor binding to PPREs or through receptor-dependent
transrepression. In addition, PPAR-γ agonists including
15d-PGJ2 can regulate gene expression through receptor-
independent mechanisms. For example, 15d-PGJ2 blocks I-
κB degradation by inhibiting the activation of I-κB kinase
resulting in the retention of NF-κB in the cytoplasm [13, 14].
In addition, 15d-PGJ2 has been demonstrated to inhibit NF-
κB binding to NF-κB DNA-response elements [15]. Thus,
in summary, PPAR-γ agonists can regulate gene expression
through both receptor-dependent and receptor-independent
mechanisms.
2. EFFECTS OF PPAR-γ ON IMMUNE CELL FUNCTION
2.1. CNSresidentcells
Microglia are bone marrow-derived cells that migrate to
the CNS during embryonic development. Normally, these
cells exist in a quiescent state in the CNS. Likewise,
astrocytes, resident CNS cells that protect neurons through
production of neurotrophic factors as well as uptake of
glutamate and other neurotoxic molecules, commonly are
quiescent in the CNS. However, these glial cells may become
activated in response to insults including stress, trauma,
and pathogens, and under these conditions may initiate
protective immune responses. Upon activation, microglia
and astrocytes produce proinﬂammatory molecules includ-
ing nitric oxide (NO), cytokines, and chemokines. These
proinﬂammatory molecules play critical roles in removing
pathogens and debris from the infected or injured CNS. In
contrast, chronically activated glia are believed to contribute
to CNS damage characteristic of neuroinﬂammatory and
neurodegenerative disorders including MS.
Van Eldik et al. were the ﬁrst to evaluate the eﬀects of
PPAR-γ agonists on immune function in glial cells. They
demonstrated that the PPAR-γ agonist 15d-PGJ2 inhibited
LPS induction of NO and iNOS expression in the murine
BV-2 microglial cell line. However, troglitazone which is a
PPAR-γ agonist and thiazolidinedione did not suppress LPS
induction of these molecules. These results were interpreted
to indicate that 15d-PGJ2 functioned through a receptor-
independent mechanism. Using the same BV-2 microglial
cell system, the Van Eldik laboratory also demonstrated
that 15d-PGJ2 suppressed LPS induction of TNF-α,I L - 1 β,
and COX-2 [16]. However, 15d-PGJ2 increased intracellular
glutathione levels as well as expression of heme oxygenase-
1, an enzyme known to stimulate antioxidant production
[17]. Minghetti et al. were the ﬁrst to investigate the
eﬀects of PPAR-γ agonists on immune function in primary
microglia. These studies indicated that 15d-PGJ2 as well as
the thiazolidinedione ciglitazone suppressed LPS induction
of iNOS and TNF-α expression by primary rat microglia.
These PPAR-γ agonists also suppressed IFN-γ induction
of major histocompatibility class II in these cells. Because
15d-PGJ2 and ciglitazone eﬀects on microglial immune cell
function were similar in these studies, it was interpreted
that 15d-PGJ2 functioned through a receptor-dependent
mechanism [18].
More recently, we compared the eﬀects of a series
of thiazolidinediones or 15d-PGJ2 on the production of
proinﬂammatory molecules by primary microglia and astro-
cytes. These studies demonstrated that both thiazolidine-
diones and 15d-PGJ2 inhibited the production of NO, the
proinﬂammatory cytokines TNF-α,I L - 1 β, and IL-6, and
the chemokine MCP-1 by these glial cells [19]. However,Paul D. Drew et al. 3
even though 15d-PGJ2 binds PPAR-γ with less aﬃnity
than each of the thiazolidinediones, this cyclopentenone
prostaglandin more strongly inhibited production of these
proinﬂammatory molecules by the glial cells, suggesting that
15d-PGJ2 acts at least in part through receptor-independent
mechanisms. A receptor-dependent eﬀect of 15d-PGJ2 in
regulating glial cell immune function is supported by studies
demonstrating that microglial cell activation is suppressed in
a cooperative manner by this PPAR-γ ligand in combination
with 9-cis retinoic acid, the ligand for the retinoic acid
receptor RXR [20]. This supports the hypothesis that glial
cell activation is maximally suppressed in the presence of
ligands following formation of PPAR-γ/RXR heterodimers.
Our observation that monocyte/microglia and astrocytes
express increased levels of PPAR-γ during active EAE
suggests that this receptor may modulate disease, perhaps
through eﬀects on glial cell activation [21]. Luna-Medina et
al. [22] demonstrated that thiazolidinediones inhibited LPS
induction of proinﬂammatory molecules by microglia and
astrocytes. In addition, thiazolidinedione treatment of glial
cultures suppressed the production of neurotoxic molecules.
The eﬀects of thiazolidinediones on glia in these studies
were abrogated by PPAR-γ antagonists suggesting a receptor-
dependent mechanism [22]. Minghetti et al. demonstrated
thattwoﬂurbiprofenderivativesdemonstratedtoreleaseNO
suppressed glial cell activation through activation of PPAR-γ
[23, 24]. Interestingly, one of these compounds, NXC 2216,
initially activated the receptor, but later stimulated nitra-
tion and inactivation of PPAR-γ [24]. This suggested that
these ﬂurbiprofen derivatives could diﬀerentially activate or
suppress glial immune cell function depending on length of
treatment.Interestingly,PGA2 potentlysuppressedmicroglia
and astrocyte production of proinﬂammatory molecules
[25]. Structurally, PGA2 is a cyclopentenone prostaglandin
like 15d-PGJ2. However, PGA2 is not believed to bind PPAR-
γ, suggesting that the cyclopentenone ring structure itself
may modulate glial cell activation.
Astrocytes, like microglia, react to pathogens through a
series of pattern recognition receptors which stimulate toll-
like receptor signaling [26, 27]. Kielian et al. demonstrated
that both 15d-PGJ2 and the thiazolidinedione ciglitazone
suppressed Staphylococcus aureus induction of NO and IL-
1β by primary astrocytes. Suppression of these proinﬂam-
matory molecules by 15d-PGJ2 and ciglitazone occurred in
both wild-type and PPAR-γ deﬁcient astrocytes, suggesting
that these compounds mediated their eﬀects in a receptor-
independent manner [28].
PPAR-γ agonists have been demonstrated to modulate a
variety of signaling pathways. Singh et al. showed that 15d-
PGJ2 inhibited LPS induction of NO and proinﬂammatory
molecules in primary astrocytes. Transfection of wild-type
PPAR-γ, dominant-negative PPAR-γ,o rt r e a t m e n to fc e l l s
with a PPAR-γ antagonist did not alter 15d-PGJ2 eﬀects
on astrocytes in these studies suggesting that the agonist
functionedthroughareceptor-independentmechanism.The
PPAR-γ agonist decreased NF-κB activity in these studies,
presumably by inhibiting I-κB kinase. Singh et al. also
demonstratedthat15d-PGJ2 inhibitedthephosphatidylinos-
itol 3-kinase-Akt signaling pathway, suggesting an additional
mechanism by which the agonist inhibited production of
proinﬂammatory molecules in astrocytes [29]. Additional
studies indicated that both the thiazolidinedione ciglitazone
and 15d-PGJ2 stimulated MAP kinase pathways in astro-
cytes through receptor-independent mechanisms involving
production of reactive oxygen species [30]. The PPAR-γ
agonists rosiglitazone and 15d-PGJ2 also were demonstrated
to modulate the JAK/STAT pathway by inhibiting the phos-
phorylation of speciﬁc JAK and STAT molecules following
induced expression of suppressor of cytokine signaling
(SOCS) 1 and 3 proteins in astrocytes and microglia [31].
Collectively, the studies discussed above suggest that
PPAR-γ agonists may regulate immune function in glia
through receptor-dependent or alternatively through re-
ceptor-independent mechanisms. Factors that may deter-
mine if receptor-dependent or receptor-independent mech-
anisms are employed may include the speciﬁc PPAR-γ
agonist studied, the concentration of the agonist used, and
the cell type studied. For example, responses are likely to
diﬀer between primary and transformed cells and may vary
depending on the developmental state of the tissue from
which the glial cells are derived.
The function and phenotype of T cells can be dra-
matically altered by glia. For example, the IL-12 family of
cytokines which includes IL-12, IL-23, and IL-27 is believed
to alter T cell phenotype and modulate the development of
EAE and MS [32]. Speciﬁcally, the IL-12 family of cytokines
modulates the diﬀerentiation of Th1 cells which are believed
to contribute to the development of EAE. In addition,
IL-23 contributes to the production of Th17 cells which
have recently been demonstrated to play a critical role in
autoimmunity. IL-12 family members are heterodimeric. IL-
12consistsofadimerofp40andp35subunits.IL-23consists
of the same p40 subunit in association with p19. IL-27 exists
as a dimer of p28 in association with EBV-induced molecule
3 (EBI3). Previously, we demonstrated that the PPAR-γ
agonist 15d-PGJ2 potently inhibited LPS induction of IL-12
p40 secretion by N9 mouse microglial cells and primary rat
microglia [33]. More recently, we demonstrated that 15d-
PGJ2 and the thiazolidinedione rosiglitazone inhibited LPS
induction of IL-12 p40, IL-12 p70, IL-23, and IL-27 p28
in primary microglia. In addition, 15d-PGJ2 inhibited IL-
12 p40, IL-23, and IL-27 p28, while rosiglitazone inhibited
IL-23, and IL-27 p28, but not IL-12 p40 in primary
astrocytes. LPS did not stimulate the production of IL-12
p70 in astrocytes [34]. These studies suggest that PPAR-γ
agonists may modulate the development of EAE in part by
modulating IL-12 family cytokine production by glia, which
may alter T cell phenotype. Costimulatory molecules may be
expressed by antigen presenting cells (APCs) including CNS
microglia. Interaction of costimulatory molecules including
CD40, CD80, and CD86 on APCs with their cognate
receptors present of CD4+ T cells is important in the
activation and diﬀerentiation of these T cells, which likewise
modulate the development of EAE and possibly MS. Our
previousstudiesindicatedthat15d-PGJ2 inhibitedmicroglial
expression of CD40, but had no eﬀect on the expression
of CD80 and CD86 costimulatory molecules. Therefore,
through modulation of costimulatory molecule expression4 PPAR Research
by microglia, PPAR-γ agonists may alter the pathogenesis of
EAE [21, 35].
PPAR-γ agonists can alter the viability of neurons and
oligodendrocytes, which are CNS cells compromised in MS.
These agonists may alter the viability of these cells directly
or indirectly by suppressing the production of cytotoxic
molecules by activated microglia and astrocytes. Combs et
al. [36] demonstrated that treatment of glial cultures with a
variety of PPAR-γ agonists suppressed β-amyloid mediated
toxicity of cortical neurons. Similarly, PPAR-γ agonists
including thiazolidinediones and 15d-PGJ2 inhibited LPS
induction of neuronal cell death in studies utilizing a rat
cortical neuron-glial coculture paradigm [37]. Furthermore,
more recent studies indicated that thiazolidinediones treat-
ment of cortical neuron-mixed glia cocultures resulted in
protection of neurons. Neuron protection was abrogated in
these studies by a PPAR-γ antagonist suggesting that neuron
protection occurred by a receptor-dependent mechanism
[22]. In addition to protecting neurons through suppression
of glial activation, PPAR-γ agonists can also directly protect
neurons. For example, PPAR-γ agonists have been demon-
stratedtoprotectneuronsfromavarietyofneurotoxicagents
including NMDA [38] and apolipoprotein E4 [39]. Interest-
ingly, neurons express PPAR-γ and several studies suggest
that neuron cell viability may be mediated through PPAR-
γ activation [40, 41]. However, the mechanisms by which
PPAR-γ regulates neuron cell viability have not been fully
elucidated. Recent studies suggest that one mechanism by
which PPAR-γ agonists may modulate neuron cell viability
is through modulation of the antiapoptotic factor Bcl-2 [42].
Interestingly, PPAR-γ also regulates neural stem cell prolifer-
ation and diﬀerentiation [43]. Less is known concerning the
role of PPAR-γ in modulating oligodendrocyte cell viability
and diﬀerentiation. However, studies suggest that PPAR-γ
protects oligodendrocyte progenitors [44] and modulates
oligodendrocyte diﬀerentiation [45].
2.2. Peripheralimmunecells
As mentioned previously, autoreactive T cells are believed
to contribute to MS pathogenesis. Clark et al. initially
demonstrated that T cells express PPAR-γ and that 15d-
PGJ2 and ciglitazone inhibited T cell secretion of IL-2 and
altered T cell proliferation [46]. PPAR-γ agonists have been
demonstrated to induce apoptosis of T cells [47]. However,
others studies indicate that PPAR-γ agonists promote the
survival of T cells [48]. The exact reason for the discrepancy
betweenthesestudiesisnotclear,butmayinvolvediﬀerences
in the concentration of PPAR-γ agonists used in the studies.
Regulatory T cells play a critical role in suppressing the
development of autoimmune diseases. Interestingly, recent
studiesindicatethatPPAR-γ agonistsenhancethegeneration
andfunctionofregulatoryTcells[49,50].Itisnowclearthat
B cells have a signiﬁcant role in modulating EAE and MS.
Phipps et al. demonstrated that B cells express PPAR-γ and
that PPAR-γ agonists stimulate the apoptosis of these cells
[51, 52]. Collectively, these studies suggest that PPAR-γ may
modulate MS in part by altering the viability and function of
lymphocytes.
As stated previously, macrophages express PPAR-γ and
PPAR-γ agonists regulate the function of these cells [53].
Like macrophages, dendritic cells are also of monocytic
origin and function as professional antigen presenting cells.
Dendritic cells also play a signiﬁcant role in MS [54,
55]. Interestingly, PPAR-γ agonists have been shown to
alter the viability and function of dendritic cells [56].
For example, cyclopentenone prostaglandins induced the
apoptosis of dendritic cells, although apoptosis occurred
through a receptor-independent mechanism [57]. PPAR-
γ agonists were also shown to inhibit the migration of
dendritic cells [58]. Furthermore, PPAR-γ agonists inhibited
toll-like receptor mediated activation of dendritic cells by
suppressing MAP kinase and NF-κB signaling pathways [59].
PPAR-γ eﬀects on dendritic cell function have also been
demonstrated to contribute to the development of CD4+
Tc e l la n e r g y[ 60]. Collectively, these studies indicate that
PPAR-γ agonists may modulate MS in part through eﬀects
on monocytic cells.
Activated peripheral immune cells including antigen
speciﬁc T cells and macrophages are capable of entering the
CNS and contributing to MS pathology. Extravasation of
peripheral immune cells is mediated by a variety of factors
including chemokines and adhesion molecule expression
on the cerebral vascular endothelium. Chemokines are
synthesized under inﬂammatory conditions and generate a
concentration gradient to which cells with the appropriate
chemokine receptors migrate. The expression of speciﬁc
chemokines is increased in EAE and MS [61, 62]. PPAR-
γ agonists decrease the expression of MCP-1 which is a
chemoattractant for monocytes and microglia [63, 64]a s
well as the T cell chemoattractants IP-10 (CXCL3), Mig
(CXCL3), and I-TAC (CXCL3) [65]. Adhesion molecules
present on the cerebral vascular endothelium facilitate
extravasation of peripheral immune cells into the CNS.
PPAR-γ agonists modulate the expression of various speciﬁc
adhesion molecules suggesting an additional mechanism
controlling immune cell extravasation into the CNS [66–
68]. Future studies will be important in determining more
detailed mechanisms by which PPAR-γ agonists modulate
immune cell movement into the CNS.
3. EFFECTS OF PPAR-γ AGONISTS ON EAE
AND MULTIPLE SCLEROSIS
3.1. EAE
EAE is a well-established animal model of MS. The disease
is induced following immunization of CNS antigens, is
mediated by myelin-speciﬁc T cells, and is characterized by
CNS inﬂammation, demyelination, and remittent paralysis
[1]. The blood-brain-barrier is believed compromised in
EAE. However,therelative bioavailability of PPAR-γ agonists
into the CNS varies, and it is important to consider this
variable when interpreting studies designed to evaluate the
eﬀects on these agonists on EAE [69, 70]. The eﬀects of
PPAR-γ agonists in modulating EAE were ﬁrst investigated
by Niino et al. who demonstrated that the thiazolidinedione
troglitazone inhibited the development of EAE elicited byPaul D. Drew et al. 5
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Figure 1: Eﬀects of PPAR-γ on immune cell function. Glial cells including microglia and astrocytes may become activated in response
to inﬂammatory stimuli including stress, trauma, and pathogens. Upon activation, microglia, and astrocytes produce a wide range of
cytokines as well as NO. These molecules may be toxic to CNS cells, including myelin-producing oligodendrocytes and neurons, which
are compromised in the course of MS. PPAR-γ agonists block the activation of glial cells resulting in repression of production of cytokines
and NO, and protect oligodendrocytes and neurons from the toxic eﬀects of these molecules. PPAR-γ agonists can also directly protect
neurons from a variety of neurotoxic agents including NMDA and apolipoprotein E4. Chemokines secreted by activated glia cells establish
a concentration gradient to which target cell populations migrate, and play important roles in recruiting cells into inﬂammatory sites in the
CNS. PPAR-γ agonists may regulate the extravasation of peripheral immune cells into the CNS by suppressing chemokine expression. In
addition, activated microglia serve as the major antigen-presenting cells (APCs) in the CNS, and dendritic cells and macrophages serve as
APCs in the periphery. These APCs are capable of secreting IL-12 family cytokines upon activation. IL-12 and IL-23 play a critical role in the
development of Th1 and Th17 cells. PPAR-γ agonists may inhibit Th1 and Th17 cell production by repressing IL-12 family cytokine secretion
by these APCs, which is believed to protect against EAE/MS.
MOG35–55 immunization of C57BL/6 mice. Troglitazone did
not alter T cell proliferation or T cell production of IFN-γ in
vitro in these studies [71]. We demonstrated that 15d-PGJ2
inhibited the proliferation of splenic MBPAc1-11 transgenic
T cells and inhibited IL-4 and IFN-γ production by these
cells in vitro [21]. In vitro treatment of these transgenic
T cells with 15d-PGJ2 decreased the encephalitogenicity of
these cells following adoptive transfer into na¨ ıve mice. This
PPAR-γ agonist also inhibited the development of EAE when
administered prior to or following onset of disease in an
active model of disease involving immunization of B10.PL
mice with MBPAc1-11 [21]. These studies suggest that PPAR-
γ agonists may be eﬀective in the treatment of established
MS. Feinstein et al. demonstrated that monophasic EAE
was inhibited by thiazolidinediones including pioglitazone.
Although pioglitazone had no eﬀect on the initial phase of
relapsing-remitting EAE, disease severity was reduced upon
subsequent relapses. In addition, these studies demonstrated
that pioglitazone protected against axonal demyelination
[72]. Bright et al. demonstrated that the PPAR-γ agonists
15d-PGJ2 and ciglitazone decreased IL-12 expression and
diﬀerentiation of Th1 cells which was associated with
decreased severity of active and passive EAE [73]. This
team of investigators later showed that heterozygous PPAR-
γ deﬁcient mice demonstrated more severe EAE than wild-
type mice [74]. They also demonstrated that more severe
EAEdevelopedfollowingtreatmentwithPPAR-γ antagonists
[75]. We showed that a combination of the PPAR-γ agonist
15d-PGJ2 and the RXR agonist 9-cis retinoic acid coopera-
tively inhibited the development of EAE [20]. Collectively,
these studies support a role for PPAR-γ in modulating EAE.
Homozygous PPAR-γ mutations arelethal thus complicating
additional studies designed to evaluate the role of this
receptor in modulating disease. Development of conditional
PPAR-γ knockout mice as well as highly speciﬁc PPAR-γ
antagonistswillhelpdeﬁnetheroleofPPAR-γ inmodulation
of EAE.
3.2. MS
Heneka et al. investigated the eﬀects of thiazolidinediones
pioglitazone and ciglitazone and the nonthiazolidinedione
PPAR-γ agonist GW347845 on the function of peripheral
blood mononuclear cells (PBMCs) from MS patients and
healthy donors. These studies demonstrated that all of
thesePPAR-γ agonistsdecreasedphytohemagglutinin(PHA)
induced T cell proliferation and production of the cytokines
TNF-α and IFN-γ by PBMCs. Interestingly, proliferation
and cytokine secretion were further suppressed following
pretreatment of cells with PPAR-γ agonists. These studies6 PPAR Research
also demonstrated that the PPAR-γ agonists decreased bcl-
2 expression and induced apoptosis of activated T cells
[76]. Additional studies by the same group indicated that
PPAR-γ expression was reduced in PBMCs from MS patients
relative to healthy donors, which correlated with decreased
anti-inﬂammatory eﬀects of pioglitazone on patient-derived
PBMCs [77]. PHA stimulation of PBMCs from healthy
donors resulted in decreased PPAR-γ expression, which was
overcamebypretreatmentofthesecellswithPPAR-γ agonist.
Long-term treatment of diabetes patients with pioglitazone
also overcame the decrease in PPAR-γ expression in PHA
treated PBMCs from these patients. These studies indi-
cate that pioglitazone treatment in humans can protect
a g a i n s tl o s so fP P A R - γ expression resulting from inﬂam-
mation. These studies also indicated that preincubation of
PBMCs with pioglitazone resulted in increased PPAR-γ and
decreased NF-κB DNA-binding activity [77]. Collectively,
thesestudiessuggestthatsustainedactivationofPPAR-γ may
preventinﬂammationinducedreductionoftheexpressionof
this receptor. These studies may have important implications
concerning the use of PPAR-γ agonists in the treatment of
MS.
A small clinical study supports the idea that PPAR-
γ agonists may be eﬀective in the treatment of MS [78].
Larger scale clinical trials are currently underway to further
assess the therapeutic potential of PPAR-γ agonists for the
treatment of MS.
4. CONCLUSIONS
PPAR-γ agonists have been demonstrated to limit pathology
in animal models of human neuroinﬂammatory and neu-
rodegenerative disorders. These studies suggest that these
agonists may be eﬀective in the treatment of human diseases
including MS. Type II diabetes is commonly treated with
PPAR-γ agonists termed thiazolidinediones which include
pioglitazone and rosiglitazone. These medications have an
excellent safety proﬁle which should facilitate future clinical
trials designed to evaluate the eﬃcacy of these PPAR-
γ agonists in the treatment of human disorders of the
CNS. However, basic research designed to better understand
the cellular and molecular mechanisms by which PPAR-
γ agonists regulate CNS inﬂammation will be critical in
developing more eﬀective treatment strategies for neuroin-
ﬂammatory disorders including MS.
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